Skip to main content

Advertisement

Table 1 Prevalence of all somatic mutations identified by UDT-Seq using a 5% prevalence detection threshold

From: Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing

Cancer   Validation Prevalence estimated by UDT-Seq
type Mutation assay Primary Xenograft Xenograft + WGA
Colon FGFR3-R327C Sanger 0.47 0.59  
  CSF1R-R710H SNaPshot 0.43 0.56  
  APC-R405X SNaPshot 0.42 0.51  
  APC-R230C Not assayed 0.4 0.49  
  KRAS-G12D SNaPshot 0.35 0.51  
  TP53-intron SNaPshot 0.35 0.47  
  NF1-P1553H SNaPshot 0.32 0.51  
  APC-R283X SNaPshot 0.23 0.49  
  BRAF-intron Not assayed 0.1 < 0.05  
  KIT-R49C Sanger 0.1 < 0.05  
  STK11-R304W SNaPshot < 0.05* 0.66  
  HRAS-R73C SNaPshot < 0.05 0.55  
  FGFR1-L457V SNaPshot < 0.05 0.44  
Breast HRAS-G12V Not assayed 0.51 0.48 0.48
Ovarian TP53-R248Q Not assayed   1  
  1. *Inspection showed it to be a false negative (present by visual inspection). Independently validated mutations (or absence thereof) are indicated in bold. WGA, whole genome amplification.